Clinical trial
Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast…
NCT00005817 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005817 |
|---|---|
| Title | Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer |
| Official title | A Randomized Phase 2 Study of Rebeccamycin Analog in Advanced Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | becatecarin, laboratory biomarker analysis |
| Enrollment | 42 |
| Start date | Mar 1, 2000 |
| Primary completion | May 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: